Whether you're looking for a gift for a science enthusiast or proud Longhorn in your life, or you're just seeking your next relaxing read, this roundup of recent books by or featuring members of the Texas Science community will come in handy.
A foundation that has set a goal this decade of identifying 50 inventors who will shape the next 50 years has added its second University of Texas at Austin faculty member to the list. The Gordon and Betty Moore Foundation announced Livia Eberlin, assistant professor in the Department of Chemistry, is one of this year's five Moore Inventor fellows.
A team of researchers at The University of Texas at Austin has demonstrated a new way to sequence proteins that is much more sensitive than existing technology, identifying individual protein molecules rather than requiring millions of molecules at a time. The advance could have a major impact in biomedical research, making it easier to reveal new biomarkers for the diagnosis of cancer and other diseases, as well as enhance our understanding of how healthy cells function.
Livia Schiavinato Eberlin, an assistant professor of chemistry at The University of Texas at Austin, has won a MacArthur Foundation Fellowship, sometimes called a "genius" award. The prestigious, no-strings-attached five-year fellowship awards $625,000 to each recipient.
James P. Allison, a world-renowned pioneer of cancer immunotherapy, has been awarded the 2018 Nobel Prize in physiology or medicine jointly with Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation."
Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy.
The Cancer Prevention and Research Institute of Texas (CPRIT) has announced that Can Cenik has been awarded a $2 million Faculty Recruitment Grant. The program recruits emerging investigators pursuing their first faculty appointment who have the ability to make outstanding contributions to the field of cancer research.
Updated on August 31, 2018: This release was updated to correct mistakes in descriptions of the way cancer cells develop drug resistance and the way that anti-cancer drug DCA affects the metabolism of cancer cells.
A new drug lead shows promise that it could reduce the size of cancerous tumors much more effectively than current treatments.
In the same way that barcodes on your groceries help stores know what's in your cart, DNA barcodes help biologists attach genetic labels to biological molecules to do their own tracking during research, including of how a cancerous tumor evolves, how organs develop or which drug candidates actually work. Unfortunately with current methods, many DNA barcodes have a reliability problem much worse than your corner grocer's. They contain errors about 10 percent of the time, making interpreting data tricky and limiting the kinds of experiments that can be reliably done.
Forty years ago, when James Allison had just gotten his PhD in biochemistry, he was intrigued by this far-out idea that was floating around about a new way to treat cancer. The idea—dubbed cancer immunotherapy—was to train the body's immune system to attack cancer cells—the same way this system already goes after bacteria and viruses. He was one of the few people who actually believed it could work.
Read our publication, The Texas Scientist, a digest covering the people and groundbreaking discoveries that make the College of Natural Sciences one of the most amazing and significant places on Earth.
